Compare USIO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USIO | CRDF |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5M | 67.1M |
| IPO Year | 1999 | 2012 |
| Metric | USIO | CRDF |
|---|---|---|
| Price | $2.09 | $0.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.92 | ★ $6.28 |
| AVG Volume (30 Days) | 207.6K | ★ 346.5K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $28,200,535.00 | $365,993.00 |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $12.26 | $5.62 |
| P/E Ratio | $102.25 | ★ N/A |
| Revenue Growth | 12.69 | ★ 49.61 |
| 52 Week Low | $1.03 | $0.71 |
| 52 Week High | $3.29 | $3.31 |
| Indicator | USIO | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 29.78 | 49.18 |
| Support Level | $1.10 | $0.77 |
| Resistance Level | $3.08 | $1.13 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 9.70 | 68.37 |
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.